RIA
HOWL icon

Regal Investment Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Regal Investment Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,593
Closed -$33.3K – 664
2025
Q4 		$33.3K Buy
52,593
+25,389
+93% +$30.9K ﹤0.01% 581
2025
Q3 		$53.6K Hold
27,204
– – ﹤0.01% 513
2025
Q2 		$29.7K Hold
27,204
– – ﹤0.01% 479
2025
Q1 		$26.4K Hold
27,204
– – ﹤0.01% 459
2024
Q4 		$40.3K Buy
27,204
+12,745
+88% +$26K ﹤0.01% 463
2024
Q3 		$30.7K Buy
+14,459
New +$32.9K ﹤0.01% 498

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Regal Investment Advisors's HOWL Position: Q1 2026 in Review

Regal Investment Advisors sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 52,593 shares — an estimated $33.3K sold.

Regal Investment Advisors first reported a position in HOWL in Q3 2024 and held it in 6 quarters. The position peaked at $53.6K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Regal Investment Advisors reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Regal Investment Advisors sold 52,593 Werewolf Therapeutics shares in Q1 2026, an estimated $33.3K.
  • Regal Investment Advisors first reported a position in Werewolf Therapeutics in Q3 2024 and held it in 6 quarters.
  • Regal Investment Advisors's Werewolf Therapeutics position peaked at $53.6K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Regal Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.